While standard lipid screening plays an important role in risk assessment, residual cardiovascular risk can still be significant despite management of traditional risk factors.1
Recent data suggests that even after statin therapy, residual risk still exists in many patients.2
Going beyond standard lipid panels to assess lipoprotein and apolipoprotein risk factors may provide deeper insights into the residual risk of your patients.
Cardiovascular risk assessment has evolved beyond lipid values to include inflammation, lipoprotein subfractions, and apolipoproteins. With deeper insights, you can take further action to help reduce your patients’ risk for adverse cardiovascular events.
This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.